Literature DB >> 11005489

Selective total mesorectal excision for rectal cancer.

A F Leong1.   

Abstract

PURPOSE: Total mesorectal excision has been advocated for rectal cancer, but its use in upper rectal and rectosigmoid tumors remains a point of debate.
METHODS: One hundred seventeen patients with rectal cancers were subjected to a prospective policy of total mesorectal excision for mid and low rectal cancers and a wide (5 cm) distal margin mesorectal excision for upper rectal and rectosigmoid cancers.
RESULTS: Forty-one patients underwent ultralow anterior resection, 10 underwent abdominoperineal excision, 64 had anterior resection and 2 had Hartmann's procedure. The median follow-up was 39 months. Forty-three patients had a defunctioning ileostomy. Three patients (7.3 percent) had anastomotic leaks after ultralow anterior resection with total mesorectal excision. Ninety-three patients had palliative resections. There were four locoregional recurrences in this group, giving an actuarial locoregional recurrence rate of 9.3 percent at five years. The actuarial locoregional recurrence rate after anterior resection was 6.5 percent at five years. The actuarial five-year cancer-specific survival rate was 81.4 percent at five years.
CONCLUSION: These results demonstrate that a policy of wide excision of the mesorectum for upper rectal and rectosigmoid cancer and total mesorectal excision for mid and low rectal cancer is associated with a low locoregional recurrence rate and may be as efficacious as routine total mesorectal excision for all rectal cancers.

Entities:  

Mesh:

Year:  2000        PMID: 11005489     DOI: 10.1007/bf02237427

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  12 in total

Review 1.  Total Mesorectal Excision Technique-Past, Present, and Future.

Authors:  Joep Knol; Deborah S Keller
Journal:  Clin Colon Rectal Surg       Date:  2020-04-28

2.  Using p53-immunostained large specimens to determine the distal intramural spread margin of rectal cancer.

Authors:  Zhi-Zhong Pan; De-Sen Wan; Chang-Qing Zhang; Jian-Yong Shao; Li-Ren Li; Gong Chen; Zhi-Wei Zhou; Fu-Long Wang
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

3.  Total mesorectal excision: what are we doing?

Authors:  David B Stewart; David W Dietz
Journal:  Clin Colon Rectal Surg       Date:  2007-08

4.  Does total mesorectal excision require a learning curve? Analysis from the database of a single surgeon's experience.

Authors:  Seung Yeop Oh; Young Bae Kim; Ok Joo Paek; Kwang Wook Suh
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

5.  [Present treatment strategies for rectal carcinoma].

Authors:  T Liersch; C Langer; B M Ghadimi; H Becker
Journal:  Chirurg       Date:  2005-03       Impact factor: 0.955

6.  Self-reported practice patterns and knowledge of rectal cancer care among Canadian general surgeons.

Authors:  Devon P Richardson; Geoff A Porter; Paul M Johnson
Journal:  Can J Surg       Date:  2014-12       Impact factor: 2.089

7.  [Problems in the treatment of upper rectal carcinoma].

Authors:  T Junginger; P Hermanek
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

8.  Short- and medium-term outcome of robot-assisted and traditional laparoscopic rectal resection.

Authors:  Alberto Patriti; Graziano Ceccarelli; Alberto Bartoli; Alessandro Spaziani; Alessia Biancafarina; Luciano Casciola
Journal:  JSLS       Date:  2009 Apr-Jun       Impact factor: 2.172

9.  Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients.

Authors:  Ji Zhu; Ye Xu; Weilie Gu; Junjie Peng; Gang Cai; Guoxiang Cai; Wenjie Sun; Weiqi Shen; Sanjun Cai; Zhen Zhang
Journal:  Radiat Oncol       Date:  2010-12-15       Impact factor: 3.481

10.  Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades.

Authors:  Armin Wiegering; Christoph Isbert; Ulrich A Dietz; Volker Kunzmann; Sabine Ackermann; Alexander Kerscher; Uwe Maeder; Michael Flentje; Nicolas Schlegel; Joachim Reibetanz; Christoph-Thomas Germer; Ingo Klein
Journal:  BMC Cancer       Date:  2014-11-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.